Consenso Paraguayo de Hipertensión Arterial 2015
Resumen
Este consenso fue ideado por el Director del Programa Nacional de Prevención Cardiovascular del M.S P. y B.S. (Paraguay) a raíz de que se necesitaba un documento actualizado que sirva como guía a los profesionales de la salud de todos los niveles de atención incluyendo a las diferentes especialidades, que tratan la hipertensión arterial y sus complicaciones agudas y crónicas. A través del convenio entre el Programa Nacional de Prevención Cardiovascular y la Sociedad Paraguaya de Cardiología de realizar actualizaciones de las Guías o documentos para difusión de manejo de patologías cardiovasculares y factores de riesgo asociados, se ha decidido elaborar y lanzar este material, que será utilizado como guía oficial en todo el territorio nacional.
Con mesas de trabajo de varios días y la colaboración de representantes de sociedades científicas afines y asesores internacionales se ha logrado esta guía. Se presentan recomendaciones para facilitar el manejo de los pacientes con hipertensión arterial y sus complicaciones, con el propósito de disminuir la morbimortalidad cardiovascular. Han sido elaboradas según las evidencias científicas y conocimiento de expertos, con un enfoque práctico y sencillo.
Todos los participantes aprobaron las decisiones finales. Los autores reconocen que la publicación y difusión de directrices serán siempre una guía práctica y que permitirá a los médicos ampliar los conocimientos con las recomendaciones propuestas, detectar precozmente el daño de órganos blancos y mejorar la calidad de vida de los pacientes hipertensos.
Citas
Ramirez MO, Pino CT, Furiasse LV, Lee AJ, Fowkes FG. Paraguayan national blood pressure study: prevalence of hypertension in the general population. J Hum Hypertens. 1995; Nov:9(11):891-7.
Organización Panamericana de la Salud, Ministerio de Salud Pública y Bienestar Social. Primera encuesta nacional de factores de riesgo para enfermedades no transmisibles /Internet/. Asunción: Ministerio de Salud Pública y Bienestar Social; 2011 /citado 21 Feb. 2016/. Disponible en: http://www.who.int/chp/steps/2011_STEPS_Paraguay_leaflet.pdf.
Organización Panamericana de la Salud, Organización Mundial de la Salud. Indicadores básicos de salud: Paraguay 2015 /Internet/. Washington, DC: OPS, OMS; 2015. /citado 21 Feb. 2016/. Disponible en: http://www.paho.org/par/index.php?option=com_docman&view=download&category_slug=datos-y-estadisticas&alias=520-paraguay-indicadores-basicos-de-salud-2015&Itemid=253
Organización Mundial de la Salud. Información general sobre la hipertensión en el mundo: una enfermedad que mata en silencio, una crisis de salud pública mundial /Internet/. Ginebra: Organización Mundial de la Salud, 2013. /citado 21 Feb. 2015/. Disponible en: http://apps.who.int/iris/bitstream/10665/87679/1/WHO_DCO_WHD_2013.2_spa.pdf
World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks /Internet/. Geneva: World Health Organization; 2009 /citado 27 Feb 2016/. Disponible en: http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf?ua=1&ua=1
Organización Panamericana de la Salud. Consulta regional: prioridades para la salud cardiovascular en las Américas: mensajes claves para los decisores. Washington, DC: OPS; 2011.
Sanchez RA, Ayala M, Baglivo H, Velazquez C, Burlando G, Kolmann O, et al. Latin American guidelines on Hypertension. Latin American Expert Group. J Hypertens. 2009; 27(5):905-22.
Zanchetti A. Consenso Latinoamericano sobre hipertensión arterial. J Hypertens. 2001; 6(2):1-28.
Cabral-Bejarano MS, González-Bogado G, Royg Brugada D. Rol de la atención primaria de salud en el abordaje integrado para el manejo de las enfermedades crónicas no transmisibles: opciones de políticas de salud en el contexto del sistema de salud del Paraguay. Asunción: Ministerio de Salud Pública y Bienestar Social; 2011.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31(7):1281–357.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC practice guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the management of arterial hypertension. J Hypertens 2007;25:1751–62.
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157(21): 2413-46.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206-52.
Consejo Argentino de Hipertensión Arterial. Consenso de hipertensión arterial. Rev Argent Cardiol. 2013; 81(supl 2):1-72.
Goff DC Jr, Lloyd-Jones DM, Bennet G, Coady S, D’Agostino RB, Robinson J, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1; 63(25):2935-59.
Souza AL, Veiga Jardim PC. Nursing and the hypertensive patient. Report of experiences. Rev Lat Am Enfermagem. 1994 Jan; 2(1):5-17.
Lopez-Jaramillo P, Sanchez RA, Diaz M, Cobos L, Bryce A, Parra-Castillo JZ, et al. Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome. Arq Bras Endocrinol Metab. 2014; 58(3):205-25.
Williams GH, Hollenberg NK. Non-modulating hypertension. A Subset of sodium-sensitive hypertension. Hypertension. 1991; 17(Suppl. 1):I81-5.
Campagnoli T, Gonzalez L, Santa Cruz F. Salt intake and blood pressure in the university of Asuncion- Paraguay youths: a preliminary study. J Bras Nefrol 2012;34(4):361-8.
Campbell NR, Lackland DT, Chockalingam A, Lisheng L, Harrap SB, Touyz RM, et al. The International Society of Hypertension and World Hypertension League call on governments, nongovernmental organizations and the food industry to work to reduce dietary sodium. J Hypertens. 2014 Feb; 32(2):446-7.
Núñez-Córdoba JM, Martínez-González MA, Bes-Rastrollo M, Toledo E, Beunza JJ, Alonso A. Consumo de alcohol e incidencia de hipertensión en una cohorte mediterránea: el
estudio SUN. Rev Esp Cardiol. 2009; 62:633-41.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb Ch, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA. 2014; 311(5):507-20.
SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373(22):2103–16.
Saftlas AE, Olson DR, Frank AL, Atrash HK, Pokras R. Epidemiology of preeclampsia and eclampsia in the United States. Am J Obstet Gynecol. 1990; 163(2):460–5.
Sanchez Zambrano M, Isea Pérez JE, Pizzi La Veglia R, Bajares de Lilue M, Ablan Candia F, Castro Blanchard N. 2011. Enfermedad cardiovascular en la mujer: prevención, diagnóstico y tratamiento. 2da ed. Caracas: Editorial 2 Minds Production; 2011.
James PR, Nelson-Piercy C. Management of hypertension before, during, and after pregnancy. Heart. 2004; 90(12):1499–504.
Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, Gülmezoglu AM, Temmerman M, Alkema L.. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun; 2(6):e323-33.
Levine RJ, Ewell MG, Hauth JC, Curet LB, Catalano PM, Morris CD, Choudhary G, Sibai BM. Should the definition of preeclampsia include a rise in diastolic blood pressure of >/=15 mm Hg to a level <90 mm Hg in association with proteinuria? Am J Obstet Gynecol. 2000; 183(4):787–92.
Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32(24):3147-97.
Fescina R, De Mucio B, Ortiz El, Jarquin D. Guías para la atención de las principales emergencias obstétricas. Montevideo: OPS, Centro Latinoamericano de Perinatología, Salud de la Mujer y Reproductiva (CLAP/SMR); 2012. (Publicación científica CLAP/SMR 1594).
Voto LS, lllia R. Darbon- Grosso HA, Imaz FU, Margulies M. Uric acid levels: a useful index of the severity of preeclampsia and perinatal prognosis. J Perinat Med. 1988; 16(2): 123-6.
Gutierrez-Aguirre CH, Alatorre-Ricardo J, Cantu-Rodriguez O, Gomez-Almaguer D. Síndrome HELLP, diagnóstico y tratamiento. Rev Hematol Mex. 2012; 13(4):195-200.
Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007; 131(6):1949-62.
Ghanem FA, Movahed A. Use of antihypertensive drugs during pregnancy and lactation. Cardiovas Ther. 2008; 26(1):38-49.
Mequid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005; 365(9456):331-40.
Santamaria-Olmo R, Gorostidi-Perez M. Presión arterial y progresión de la enfermedad renal crónica. NefroPlus. 2013; 5(1):4-11.
Klag MJ, Welton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996; 334(1):13-8.
Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE, et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: The kidney Early Evaluation Program (KEEP). Arch Intern Med. 2012; 172(1):41-7.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1-266.
Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from kidney disease improving global outcomes. Kidney Int. 2007; 72(3): 247-59.
Perera GA. Hypertensive vascular disease; description and natural history. J Chronic Dis. 1955; 1(1):33-42.
Palmer BF. Impaired renal autoregulation: implications for the genesis of hypertension and hypertension-induced renal injury. Am J Med Sci. 2001; 321(6):388-400.
Udani S, Lazich I, Bakris GL. Epidemiology of hypertensive kidney disease. Nat Rev Nephrol. 2011; 7(1):11-21.
Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J, et al. US renal data system 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015; 66 (1 Suppl 1):S1-305.
Ritz E, Adamczak M, Zeier M. Kidney and hypertension-causes. Herz. 2003; 28(8):663-7.
Abdi R, Brenner BM. Impact of renin angiotensin system blockade on renal function in health and disease: an end or a beginning? Semin Nephrol. 2004; 24(2):141-6.
Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int. 2004; 65(5):1568-76.
Ramírez-Sandoval JC. Referencia temprana al nefrólogo del paciente con enfermedad renal crónica. Focus Renal. 2012; 3(1): 3-7.
Kidney Disease Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. Suppl 2012; 2:S337-S414.
National Institute for Health and Care Excellence - NICE. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. England: NICE, 2014. Clinical guideline 182.
Drawz PE, Rosenberg ME. Slowing progression of chronic kidney disease. Kidney Int Suppl. 2013; 3(4):372-6.
American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015; 38(suppl 1):S1-S93.
Schmieder RE, Gitt AK, Koch C, Bramlage P, Ouarrak T, Tschöpe D. Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry. BMC Endocr Disord. 2015 May 2;15:23.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 31(160):703-13.
Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014 Oct 9; 371(15):1392-406.
Asociación Latinoamericana de Diabetes-ALAD. Guías ALAD sobre el diagnóstico, control y tratamiento de la Diabetes Mellitus Tipo 2 con medicina basada en evidencia. Revista de la ALAD. 2013:1-142.
Gómez Angelats E, Bragulat Baur E. Hypertension, hypertensive crisis, and hypertensive emergency: approaches to emergency department care. Emergencias. 2010; 22: 209-19.
Henny-Fullin K, Buess D, Handschin A, Leuppi J, Dieterle T. Hypertensive urgency and emergency. Ther Umsch. 2015 Jun; 72(6):405-11.
Gegenhuber A, Lenz K. Hypertensive emergency and urgence. Herz. 2003 Dec; 28(8):717-24.
Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(3):870–947.
Elliott WJ. Clinical features in the management of selected hypertensive emergencies.
Prog Cardiovasc Dis. 2006; 48(5): 316-25.
Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D´Agostino RB. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J. 1996; 131(4):790–5.
Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, D´Agostino RB, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003; 107(23):2920–5.
Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA, Roger VL. Atrial fibrillation and death after myocardial infarction: a community study. Circulation. 2011; 123(19):2094–100.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991; 22(8):983–8.
Taillandier S, Olesen JB, Clementy N, Lagrenade I, Babuty D, Lip GY, Fauchier L. Prognosis in patients with atrial fibrillation and CHA2DS2- VASc Score=0 in a community-based cohort study. J Cardiovasc Electrophysiol. 2012; 23(7):708–13.
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014;130(23):2071-104.
Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45(12):3754-832.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5):1093–100.
Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349(11):1019–26.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857–67.
Van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006; 129(5):1155–66.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139–51.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883–91.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hyler EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14(8): 803-69.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62(16):e147-239.
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003.
Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362(9386):759-6.
Konstam MA, Neaton JD, Dicksteiez K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009; 374(9704): 1840–8.
Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-Sendón J, Sharpe N, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004; 109(2):201-6.
Van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure). J Am Coll Cardiol. 2009; 53(23): 2150-8.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999; 341(10): 709–17.
Rosendorff C, writing committee. Treatment of hypertension in patients with coronary artery disease. A case-based summary of the 2015 AHA/ACC/ASH scientific statement. Am J Med. 2016; 129(4):372-8.
Takashima H, Ozaki Y, Morimoto T, Kimura T, Hiro Y, Miyauchi K, et al. Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study. Circ J. 2012; 76(12): 2840 -7.
Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20): 2569–619.
